Immunotherapies targeting immune checkpoint molecules, including PD1, CTLA-4, and Tim-3 have been a major breakthrough in cancer therapy and have changed our understanding of host-tumor interactions25,26. This evidence concerns the gene HAVCR2 and neoplasm.